Litcius/Paper detail

Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors

Toshio Shimizu, Takako Eguchi Nakajima, Noboru Yamamoto, Kan Yonemori, Takafumi Koyama, Shunsuke Kondo, Yu Sunakawa, Naoki Izawa, Yoshiki Horie, Silong Xiang, Siying Xu, Lan Qin, John Gong, David Liu

2022Investigational New Drugs48 citationsDOI

Topics & Concepts

MedicineTolerabilityPharmacokineticsCmaxAdverse effectDosingInternal medicinePharmacodynamicsGastroenterologyResponse Evaluation Criteria in Solid TumorsPharmacologyPhases of clinical researchChemotherapyCancer Immunotherapy and BiomarkersCAR-T cell therapy researchLymphoma Diagnosis and Treatment
Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors | Litcius